Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569388 | 0.90 | MAPT (0.62) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4172495 | 0.86 | MAPT (0.58) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5071255 | 0.85 | MAPT (0.57) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15956633 | 0.85 | MAPT (0.57) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL22878471 | 0.84 | MAPT (0.53) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1440000 | 0.83 | MAPT (0.55) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL853489 | 0.83 | MAPT (0.55) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30414662 | 0.83 | MAPT (0.55) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL17284582 | 0.83 | MAPT (0.55) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6950591 | 0.83 | MAPT (0.55) | MAPTLMNAALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383854-A1 | PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES | HOVIONE FARMACIENCIA SA (PT) | 2024-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383854-A1 | PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES | ETFB, TOP2B, MGMT | MAPT 4023/4885LMNA 1506/4885ALDH1A1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.